Information Provided By: 
Fly News Breaks for September 10, 2019
ACAD
Sep 10, 2019 | 07:02 EDT
As reported previously, Canaccord analyst Sumant Kulkarni upgraded Arcadia after the company announced it stopped it pivotal Phase 3 HARMONY trial in dementia-related psychosis after primavanserin hit its primary endpoint. . The analyst believes this puts the company back on the short list of company/assets that present scarcity and value for strategic interests in the neuro space. Kulkarni raised his price target to $50 from $29 on Arcadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
